JP2024160287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024160287A5 JP2024160287A5 JP2024129687A JP2024129687A JP2024160287A5 JP 2024160287 A5 JP2024160287 A5 JP 2024160287A5 JP 2024129687 A JP2024129687 A JP 2024129687A JP 2024129687 A JP2024129687 A JP 2024129687A JP 2024160287 A5 JP2024160287 A5 JP 2024160287A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- aflibercept
- concentration
- polysorbate
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587733P | 2017-11-17 | 2017-11-17 | |
| US62/587,733 | 2017-11-17 | ||
| US201862618904P | 2018-01-18 | 2018-01-18 | |
| US62/618,904 | 2018-01-18 | ||
| PCT/US2018/061644 WO2019099921A2 (en) | 2017-11-17 | 2018-11-16 | Vegfr-fc fusion protein formulations |
| JP2020527828A JP7536640B2 (ja) | 2017-11-17 | 2018-11-16 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527828A Division JP7536640B2 (ja) | 2017-11-17 | 2018-11-16 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024160287A JP2024160287A (ja) | 2024-11-13 |
| JP2024160287A5 true JP2024160287A5 (enExample) | 2025-04-09 |
Family
ID=65041879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527828A Active JP7536640B2 (ja) | 2017-11-17 | 2018-11-16 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
| JP2024129687A Pending JP2024160287A (ja) | 2017-11-17 | 2024-08-06 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527828A Active JP7536640B2 (ja) | 2017-11-17 | 2018-11-16 | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12156900B2 (enExample) |
| EP (1) | EP3709971A2 (enExample) |
| JP (2) | JP7536640B2 (enExample) |
| AU (2) | AU2018368466B2 (enExample) |
| CA (1) | CA3082899A1 (enExample) |
| MA (1) | MA50908A (enExample) |
| MX (2) | MX2020005170A (enExample) |
| WO (1) | WO2019099921A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020005170A (es) | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
| EP4495136A3 (en) | 2018-01-26 | 2025-04-23 | The Regents of the University of California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| EP3761953A1 (en) * | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| SG11202010684YA (en) | 2018-05-10 | 2020-11-27 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
| WO2020055123A1 (ko) * | 2018-09-10 | 2020-03-19 | 삼성바이오에피스 주식회사 | 단백질을 포함하는 액상 조성물 |
| WO2021050687A1 (en) * | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| CA3190325A1 (en) * | 2020-07-31 | 2022-02-03 | Celltrion Inc. | Stable pharmaceutical preparation |
| US20240166718A1 (en) * | 2021-02-17 | 2024-05-23 | Arecor Limited | Aqueous composition of an engineered protein construct comprising an fc domain |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| US12240888B1 (en) * | 2024-04-29 | 2025-03-04 | QILU Pharmaceutical, Co., Ltd. | Composition comprising aflibercept and a variant thereof, and related methods and uses |
| WO2025227916A1 (zh) * | 2024-04-29 | 2025-11-06 | 齐鲁制药有限公司 | 包含阿柏西普和其变体的组合物以及相关方法和应用 |
| DE102025103344A1 (de) | 2024-09-17 | 2026-03-19 | Kioxia Corporation | Speichersystem und verfahren zur steuerung eines nichtflüchtigen speichers |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL215168B1 (pl) | 2002-02-27 | 2013-10-31 | Immunex Corp | Formulacja polipeptydowa |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| EP1877438A2 (en) | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
| EP2586459B1 (en) | 2005-03-25 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
| ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| EP3753548A1 (en) | 2006-06-16 | 2020-12-23 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CN103816115B (zh) | 2010-08-31 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| EP2790681B9 (en) | 2011-11-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying |
| ES2751386T3 (es) | 2011-12-21 | 2020-03-31 | Amgen Inc | Polipéptidos Fc variantes con unión potenciada al receptor de Fc neonatal |
| CN107115294B (zh) | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| AR091237A1 (es) | 2012-06-01 | 2015-01-21 | Ophthotech Corp | Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| US9649383B2 (en) | 2012-11-19 | 2017-05-16 | Merck Sharp & Dohme Corp. | Liquid formulations for TNFR:Fc fusion proteins |
| CN105636986B (zh) | 2013-10-18 | 2020-05-12 | 瑞泽恩制药公司 | 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物 |
| CN105435222B (zh) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| CA3001346A1 (en) * | 2015-10-16 | 2017-04-20 | Regeneron Pharmaceuticals, Inc. | Stable protein compositions |
| EA201891164A1 (ru) * | 2015-12-16 | 2018-11-30 | Ридженерон Фармасьютикалз, Инк. | Композиции и способы получения белковых микрочастиц |
| AU2017213103B2 (en) * | 2016-01-26 | 2022-08-11 | Formycon Ag | Liquid formulation of a VEGF antagonist |
| WO2017168296A1 (en) | 2016-03-29 | 2017-10-05 | Navya Biologicals Pvt. Ltd | A process for purification of fc-fusion proteins |
| KR101685532B1 (ko) | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| CA3038894A1 (en) | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| EP3528787B1 (en) | 2016-10-21 | 2026-01-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| EP3541365A1 (en) | 2016-11-21 | 2019-09-25 | Just Biotherapeutics, Inc. | Aflibercept formulations and uses thereof |
| US20200131251A1 (en) | 2016-12-23 | 2020-04-30 | Serum Institute Of India Private Limited | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
| KR101861163B1 (ko) | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| WO2019055902A1 (en) | 2017-09-18 | 2019-03-21 | Amgen Inc. | FUSION PROTEIN FORMULATIONS VEGFR-FC |
| CN107595765A (zh) | 2017-09-22 | 2018-01-19 | 沈阳兴齐眼药股份有限公司 | 一种眼用缓释药物递送系统及其制备方法 |
| MX2020005170A (es) | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
| WO2019099965A1 (en) | 2017-11-20 | 2019-05-23 | Just Biotherapeutics, Inc. | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| JP7692699B2 (ja) | 2017-12-22 | 2025-06-16 | サムスン バイオエピス カンパニー リミテッド | Ｖｅｇｆアンタゴニストを含む液体組成物 |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| EP3761953A1 (en) | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| SG11202010684YA (en) | 2018-05-10 | 2020-11-27 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
| WO2020055123A1 (ko) | 2018-09-10 | 2020-03-19 | 삼성바이오에피스 주식회사 | 단백질을 포함하는 액상 조성물 |
| US20210353713A1 (en) | 2018-10-26 | 2021-11-18 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
| WO2020165132A1 (en) | 2019-02-13 | 2020-08-20 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| GB201911461D0 (en) | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| WO2021050687A1 (en) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
-
2018
- 2018-11-16 MX MX2020005170A patent/MX2020005170A/es unknown
- 2018-11-16 JP JP2020527828A patent/JP7536640B2/ja active Active
- 2018-11-16 MA MA050908A patent/MA50908A/fr unknown
- 2018-11-16 WO PCT/US2018/061644 patent/WO2019099921A2/en not_active Ceased
- 2018-11-16 EP EP18836718.9A patent/EP3709971A2/en active Pending
- 2018-11-16 AU AU2018368466A patent/AU2018368466B2/en active Active
- 2018-11-16 US US16/764,463 patent/US12156900B2/en active Active
- 2018-11-16 CA CA3082899A patent/CA3082899A1/en active Pending
-
2020
- 2020-07-13 MX MX2025004779A patent/MX2025004779A/es unknown
-
2024
- 2024-07-31 AU AU2024205240A patent/AU2024205240A1/en active Pending
- 2024-08-06 JP JP2024129687A patent/JP2024160287A/ja active Pending
- 2024-11-25 US US18/959,137 patent/US20250082726A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024160287A5 (enExample) | ||
| JP2023055780A5 (enExample) | ||
| JP2020138981A5 (enExample) | ||
| JP2022166006A5 (enExample) | ||
| JP2020183387A5 (enExample) | ||
| JP2021169467A5 (enExample) | ||
| JP2024099682A5 (enExample) | ||
| ES2240113T3 (es) | Cristales de lansoprazol. | |
| JP2025163108A5 (enExample) | ||
| JP2024028337A5 (enExample) | ||
| JP2021503485A5 (enExample) | ||
| JP2019504086A5 (enExample) | ||
| JP2017516847A5 (enExample) | ||
| US20090220621A1 (en) | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination | |
| JPH0434966B2 (enExample) | ||
| JP2010529999A5 (enExample) | ||
| JP2012211150A5 (enExample) | ||
| JP2016164165A5 (enExample) | ||
| JP2023076632A5 (enExample) | ||
| JP2025090691A5 (enExample) | ||
| JP2015535237A5 (enExample) | ||
| CN110637022A (zh) | 可作为流感病毒复制抑制剂的吡咯并嘧啶衍生物 | |
| RU2008151945A (ru) | Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина | |
| JP2009505991A5 (enExample) | ||
| CN115697354A (zh) | 用于治疗sars-cov-2感染的组合物和方法 |